MedTrace Logo

Lowering Blood Pressure in Primary Care in Vienna

NCT02377661 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 229

Last updated 2017-08-18

No results posted yet for this study

Summary

The aim of this prospective, randomised, open-label, multicentre clinical trial is to enhance blood pressure control in primary care by introducing a standardised and simplified titration regime with single pill combinations (SPC), comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.

Conditions

Interventions

DRUG

Olmesartan medoxomil, amlodipine, hydrochlorothiazide

Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of \< 140/90 mmHg is not reached at the respective follow-up

Sponsors & Collaborators

  • Association for the Promotion of Research in Atherosclerosis, Thrombosis and Vascular Biology

    collaborator OTHER

  • Ludwig Boltzmann Foundation for Cardiovascular Research

    collaborator UNKNOWN

  • Wilhelminenspital Vienna

    lead OTHER

Principal Investigators

  • Thomas W Weiss, MD, PhD · 3rd Medical Department, Cardiology and Intensive Care Medicine Wilhelminenhospital, 1160 Vienna, Austria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-05-30
Completion
2017-05-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02377661 on ClinicalTrials.gov